Is Axcelis Stock a Buy After Doubling This Year?

Axcelis Technologies (ACLS) has doubled year-to-date despite posting just 3% year-over-year revenue growth in Q1. The ion implantation equipment maker, which supplies critical tools for AI chip production, is banking on a shift in its revenue mix to sustain the rally.

The company reported modest top-line expansion in its most recent quarter, but analysts cited by The Motley Fool expect sequential growth in memory demand to accelerate results ahead. Memory is projected to become a larger share of Axcelis' revenue, a transition analysts believe justifies further upside from current levels.

A pending merger with Veeco Instruments will broaden Axcelis' AI infrastructure portfolio and unlock operational synergies, though specific financial terms or completion timelines were not disclosed in the source material. The combination positions the merged entity to serve a wider slice of the semiconductor capital equipment market tied to AI buildouts.

The stock's 100% gain this year has come despite single-digit revenue growth, reflecting investor confidence in the memory cycle recovery and the strategic rationale behind the Veeco deal.